Skip to content

Effect of Intake of Pyrus Pyrifolia Var. Culta(Makino) NaKai Peel Extract on Body Fat and Blood Lipid.

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02742688
Enrollment
70
Registered
2016-04-19
Start date
2016-03-31
Completion date
2016-06-30
Last updated
2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Pyrus pyrifolia var. culta(Makino) NaKai peel extract on decrement of body fat. The investigators measured decrement of body fat parameters , including Body Fat Mass, Percent Body Fat, weight and BMI(body mass index), and monitored their blood pressure.

Interventions

DIETARY_SUPPLEMENTPyrus pyrifolia var. culta(Makino) NaKai peel extract

Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)

DIETARY_SUPPLEMENTPlacebo

Placebo(4g/day)

Sponsors

Hanyang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and females 19-65 years old * BMI(body mass index) 25\ 29.9 kg/m\^2 or WC(Waist Circumference) ≥ 90(men), WC ≥ 85(women) * Able to give informed consent

Exclusion criteria

* BMI(body mass index) ≥ 30 kg/m\^2 * Significant variation in weight(more 10%) in the past 3 months * Allergic or hypersensitive to any of the ingredients in the test products * History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery * History of alcohol or substance abuse * Participation in any other clinical trials within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * Pregnant or lactating women etc.

Design outcomes

Primary

MeasureTime frameDescription
Changes in body fat mass8 weekBody fat mass was measured in study baseline and visit 3(8 week)

Secondary

MeasureTime frameDescription
Change in fat free mass8 weekFat free mass was measured in study baseline and visit 3(8week)
Change in body mass index8 weekBody mass index was measured in study baseline and visit 3(8 week)
Changes in percent body fat8 weekPercent body fat was measured in study baseline and visit 3(8 week)
Change in total cholesterol8 weekTotal cholesterol was measured in study baseline and visit 3(8 week)
Change in triglyceride8 weekTriglyceride was measured in study baseline and visit 3(8 week)
Change in weight8 weekWeight was measured in study baseline and visit 3(8 week)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026